Forest Laboratories Names A. Robert D. Bailey Senior Vice President, Chief Legal Officer and General Counsel
November 11 2013 - 5:00PM
Business Wire
Forest Laboratories, Inc. (NYSE:FRX) today announced that Robert
Bailey was appointed Senior Vice President, Chief Legal Officer
General Counsel. In this role, Bailey will be responsible to manage
the legal affairs of the Company, and will also serve as the
company’s Corporate Secretary. Bailey will report to Brent
Saunders, Chief Executive Officer and President, and serve as a
member of the Forest Executive Team. Bailey succeeds Herschel
Weinstein, who served as outside legal counsel to Forest for many
years and as Forest’s General Counsel since 2006 and who will serve
as a senior legal advisor to the Company on a transitional
basis.
Commenting on the appointment of Mr. Bailey to this new
position, Brent Saunders, CEO and President said, “Bob brings to
Forest extensive experience in mergers, acquisitions and licensing
along with expertise in complex litigation, corporate governance
and securities law. Bob is a good business leader and executive
with a track record as an outstanding business partner, an
excellent advisor to management and the board of directors and a
strong legal team leader. These are essential skills for Forest as
we embark on a plan to rejuvenate the company to drive sustained
growth.”
“I thank Herschel for his many years of service to Forest
Laboratories and I appreciate his willingness to serve in an
advisory capacity during the transition. During his 30 year
association with Forest, Herschel provided excellent counsel to
senior management, developed and grew the internal legal function
and helped the company negotiate deals necessary to execute our
next 9 strategy,” said Saunders.
Bailey most recently served from 2007 to 2013 as Executive Vice
President, Law, Policy and Communications at Bausch + Lomb. Before
joining Bausch + Lomb in 1994, Bailey was an attorney at Nixon
Peabody (formerly Nixon Hargrave Devans & Doyle).
Bailey received his law degree from the University of Minnesota,
and his undergraduate degree from St. Olaf College in Northfield,
MN.
About Forest
Laboratories
Forest Laboratories' (NYSE: FRX) longstanding global
partnerships and track record developing and marketing
pharmaceutical products in the United States have yielded its
well-established central nervous system and cardiovascular
franchises and innovations in anti-infective, respiratory,
gastrointestinal and pain management medicine. Forest’s pipeline,
the most robust in its history, includes product candidates in all
stages of development across a wide range of therapeutic areas. The
Company is headquartered in New York, NY. To learn more, visit
www.FRX.com.
Except for the historical information contained herein, this
release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. These
statements involve a number of risks and uncertainties, including
the difficulty of predicting FDA approvals, the acceptance and
demand for new pharmaceutical products, the impact of competitive
products and pricing, the timely development and launch of new
products, and the risk factors listed from time to time in Forest
Laboratories' Annual Report on Form 10-K, Quarterly Reports on Form
10-Q, and any subsequent SEC filings. Forest assumes no obligation
to update forward-looking statements contained in this release to
reflect new information or future events or developments.
Forest Laboratories, Inc.Frank J. Murdolo, 1-212-224-6714Vice
President - Investor Relationsmedia.relations@frx.com
Forest Road Acquisition (NYSE:FRX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Forest Road Acquisition (NYSE:FRX)
Historical Stock Chart
From Jul 2023 to Jul 2024